Hyun Hong, MD
Interventional Pain Medicine · Olympia, WANPI 1336123827
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,242 of the $16,368 with a category attached, or 62.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 19.7%.
Across 301 payments — averaging $54.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$3K
- Vertiflex, Inc.$2K
- Globus Medical$1K
- Biotronik NRO, Inc.$1K
- Curonix LLC$1K
- plus $5K from 23 others
What the payments were for
- Consulting fees$1251%
- Travel & lodging$6,00137%
- Food & beverage$10,24263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 83 | $3,222 |
| Medtronic(2 entities) | 39 | $2,880 |
| Vertiflex, Inc. | 8 | $1,701 |
| Globus Medical | 26 | $1,352 |
| Biotronik NRO, Inc. | 10 | $1,295 |
| Curonix LLC | 7 | $1,095 |
| Nevro Corp. | 21 | $966 |
| Si-bone, Inc. | 5 | $926 |
| Boston Scientific | 10 | $406 |
| Stimwave Technologies Incorporated | 5 | $390 |
| AbbVie(2 entities) | 10 | $320 |
| Nalu Medical, Inc. | 6 | $281 |
| Collegium Pharmaceutical, Inc. | 15 | $266 |
| MDD US Operations, LLC | 10 | $211 |
| Lilly USA, LLC | 8 | $141 |
| Biodelivery Sciences International, Inc. | 9 | $130 |
| Painteq LLC | 1 | $112 |
| Vertos Medical, Inc. | 4 | $108 |
| Pfizer | 5 | $102 |
| Biohaven Pharmaceuticals, Inc. | 6 | $101 |
| Foundation Fusion Solutions, LLC | 1 | $89 |
| SPR Therapeutics, Inc | 1 | $73 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Averitas Pharma Inc. | 1 | $37 |
| Zyla Life Sciences, Inc. | 2 | $29 |
| Bioventus LLC | 1 | $24 |
| Fidia Pharma USA Inc. | 2 | $21 |
| GRT US Holding, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion ISS$1,557
- Prospera$1,181
- KYPHON EXPRESS II KYPHOPAK TRAY$1,158
- Senza$843
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$822
- IFUSE IMPLANT SYSTEM$817
- KYPHON Balloon Kyphoplasty$678
- PROCLAIM$615
- Proclaim IPG$392
- Vyrsa V1$308
- INTELLIS ADAPTIVESTIM$149
- GENERAL PAIN MANAGEMENT$138
- Nalu Neurostimulation System$125
- Lucemyra/Lofexidine$122
- PAINTEQ$112
- Omnia$106
- CFNS StimQ Peripheral Nerve StimulatorSystem$105
- SCS FreedonSpinal Cord Stimulator$105
- SlimTip lead DRG Lead$100
How this compares
$16,368 in reported general payments places this provider in the 85th percentile of 30 interventional pain medicine providers in Washington.
See all interventional pain medicine providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 84 | $68,487 |
| Buprenorphine | 225 | $50,342 |
| QuliptaAtogepant | 11 | $13,499 |
| MovantikNaloxegol Oxalate | 11 | $4,331 |
| Pregabalin | 106 | $1,621 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 104 | $1,342 |
| Tizanidine Hcl | 97 | $737 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 53 | $665 |
| Gabapentin | 54 | $627 |
| Cephalexin | 60 | $587 |
| Tramadol Hcl | 80 | $518 |
| Duloxetine Hcl | 31 | $383 |
| Morphine Sulfate | 22 | $317 |
| Celecoxib | 13 | $297 |
| Mupirocin | 33 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $266 | $68,48784 claims |
| AbbVieQulipta | $320 | $13,49911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 interventional pain medicine providers in Washington.
Other interventional pain medicine in Olympia
- Zachary AbbottOlympia$172
- Ray BakerKirkland$1.2M
- Daniel NelsonKirkland$29K
- Kyong KimLakewood$23K
- Glen DavidSeattle$14K
- Kiang Yien CheungTacoma$12K
- Diyan RazaSeattle$12K
- Kathy WangPuyallup$11K
- Allen ShohamRichland$8K
- Kashif SaeedTacoma$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.